<style> ins { background-color: #00ff00; }
del {background-color: #ff0000} </style><div><section class="epn_regular_section epn_homepage_category_feed channel-pharma"> <section class="epn_regular_section epn_home_featured"><h3 class="epn_section_title"><ins>top stories</ins></h3><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/suggested-by-bloomberg-blessed-by-analysts-could-an-ma-match-with-a-certain-ms-player-be-far-off-for-blockbuster-hungry-sanofi/" title="UPDATED: Suggested by Bloomberg, blessed by analysts, could an M&amp;A match with a certain MS player be far off for blockbuster-hungry Sanofi?">UP­DAT­ED: Sug­gest­ed by Bloomberg, blessed by an­a­lysts, could an M&amp;A match with a cer­tain MS play­er be far off for ... Link: https://endpts.com/suggested-by-bloomberg-blessed-by-analysts-could-an-ma-match-with-a-certain-ms-player-be-far-off-for-blockbuster-hungry-sanofi/ </a> </ins></h2><ins> </ins><p class="epn_time"><ins>11 hours ago</ins></p><p class="epn_channel channel-deals"><ins><a href="https://endpts.com/channel/deals/" title="Channel: Deals"><span>Deals</span> Link: https://endpts.com/channel/deals/ </a></ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/eli-lillys-mirikizumab-joins-the-club-beating-up-on-cosentyx-as-another-head-to-head-study-leaves-novartis-drug-in-the-dust/" title="Eli Lilly’s mirikizumab joins the club beating up on Cosentyx as another head-to-head study leaves Novartis’ drug in the dust">Eli Lil­ly’s mirik­izum­ab joins the club beat­ing up on Cosen­tyx as an­oth­er head-to-head study leaves No­var­tis’ drug ... Link: https://endpts.com/eli-lillys-mirikizumab-joins-the-club-beating-up-on-cosentyx-as-another-head-to-head-study-leaves-novartis-drug-in-the-dust/ </a> </ins></h2><ins> </ins><p class="epn_time"><ins>8 hours ago</ins></p><p class="epn_channel channel-rd"><ins><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span> Link: https://endpts.com/channel/rd/ </a></ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/jj-partnered-meiragtx-aims-at-biogen-with-new-eye-gene-therapy-data/" title="J&amp;J-partnered MeiraGTx aims at Biogen with new eye gene therapy data">J&amp;J-part­nered MeiraGTx aims at Bio­gen with new eye gene ther­a­py da­ta Link: https://endpts.com/jj-partnered-meiragtx-aims-at-biogen-with-new-eye-gene-therapy-data/ </a> </ins></h2><ins> </ins><p class="epn_time"><ins>6 hours ago</ins></p><p class="epn_channel channel-rd"><ins><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span> Link: https://endpts.com/channel/rd/ </a></ins></p><p class="epn_channel channel-cell-gene-tx"><ins><a href="https://endpts.com/channel/cell-gene-tx/" title="Channel: Cell/Gene Tx"><span>Cell/Gene Tx</span> Link: https://endpts.com/channel/cell-gene-tx/ </a></ins></p><h3 class="epn_section_title"><ins>Latest</ins></h3><p class="epn_item"><ins></ins></p><p class="epn_badge"><ins>Most read</ins></p><ins> </ins><h3 class="epn_headline"><ins><a href="https://endpts.com/niaid-and-moderna-spell-out-a-robust-immune-response-in-phi-coronavirus-vaccine-test-but-big-questions-remain-to-be-answered/" title="UPDATED: NIAID and Moderna spell out a 'robust' immune response in PhI coronavirus vaccine test — but big questions remain to be answered">UP­DAT­ED: NI­AID and Mod­er­na spell out a 'ro­bust' im­mune re­sponse in PhI coro­n­avirus vac­cine test — but big ques­tions ... Link: https://endpts.com/niaid-and-moderna-spell-out-a-robust-immune-response-in-phi-coronavirus-vaccine-test-but-big-questions-remain-to-be-answered/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>3 days ago</ins></p><ins> </ins><p class="epn_channel channel-rd"><ins><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span> Link: https://endpts.com/channel/rd/ </a></ins></p><p class="epn_channel channel-coronavirus"><ins><a href="https://endpts.com/channel/coronavirus/" title="Channel: Coronavirus"><span>Coronavirus</span> Link: https://endpts.com/channel/coronavirus/ </a></ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/bms-gets-the-ball-rolling-on-liso-cel-in-europe-beigene-files-china-nda-for-in-house-parp-drug/" title="BMS gets the ball rolling on liso-cel in Europe; BeiGene files China NDA for in-house PARP drug">BMS gets the ball rolling on liso-cel in Eu­rope; BeiGene files Chi­na NDA for in-house PARP drug Link: https://endpts.com/bms-gets-the-ball-rolling-on-liso-cel-in-europe-beigene-files-china-nda-for-in-house-parp-drug/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>6 hours ago</ins></p><ins> </ins><p class="epn_channel channel-protocols"><ins><a href="https://endpts.com/channel/protocols/" title="Channel: Protocols"><span>Protocols</span> Link: https://endpts.com/channel/protocols/ </a></ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/chinas-cro-powerhouse-tigermed-to-seek-1b-ipo-in-hong-kong-report/" title="China's CRO powerhouse Tigermed to seek $1B IPO in Hong Kong — report">Chi­na's CRO pow­er­house Tigermed to seek $1B IPO in Hong Kong — re­port Link: https://endpts.com/chinas-cro-powerhouse-tigermed-to-seek-1b-ipo-in-hong-kong-report/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>7 hours ago</ins></p><ins> </ins><p class="epn_channel channel-ipos"><ins><a href="https://endpts.com/channel/ipos/" title="Channel: IPOs"><span>IPOs</span> Link: https://endpts.com/channel/ipos/ </a></ins></p><p class="epn_channel channel-china"><ins><a href="https://endpts.com/channel/china/" title="Channel: China"><span>China</span> Link: https://endpts.com/channel/china/ </a></ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/in-anticipation-of-phiii-trial-results-amicus-pares-down-old-debt-with-400-million-loan/" title="In anticipation of PhIII trial results, Amicus pares down old debt with $400 million loan">In an­tic­i­pa­tion of PhI­II tri­al re­sults, Am­i­cus pares down old debt with $400 mil­lion loan Link: https://endpts.com/in-anticipation-of-phiii-trial-results-amicus-pares-down-old-debt-with-400-million-loan/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>7 hours ago</ins></p><ins> </ins><p class="epn_channel channel-rd"><ins><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span> Link: https://endpts.com/channel/rd/ </a></ins></p><p class="epn_channel channel-pharma"><ins><a href="https://endpts.com/channel/pharma/" title="Channel: Pharma"><span>Pharma</span> Link: https://endpts.com/channel/pharma/ </a></ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/tony-kingsley-takes-over-the-reins-at-scholar-rock-maat-pharma-adds-servier-cso-to-board/" title="Tony Kingsley takes over the reins at Scholar Rock; Idorsia taps pharma vet Patricia Torr for new US ops">Tony Kings­ley takes over the reins at Schol­ar Rock; Idor­sia taps phar­ma vet Pa­tri­cia Torr for new US ops Link: https://endpts.com/tony-kingsley-takes-over-the-reins-at-scholar-rock-maat-pharma-adds-servier-cso-to-board/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>10 hours ago</ins></p><ins> </ins><p class="epn_channel channel-peer-review"><ins><a href="https://endpts.com/channel/peer-review/" title="Channel: Peer Review"><span>Peer Review</span> Link: https://endpts.com/channel/peer-review/ </a></ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/covid-19-roundup-oxford-researchers-prep-for-vaccine-challenge-trials-urges-nih-to-follow-suit/" title="Covid-19 roundup: EU looks to pre-order vaccines from Moderna, Sanofi, J&amp;J, BioNTech, CureVac — report">Covid-19 roundup: EU looks to pre-or­der vac­cines from Mod­er­na, Sanofi, J&amp;J, BioN­Tech, Cure­Vac — re­port Link: https://endpts.com/covid-19-roundup-oxford-researchers-prep-for-vaccine-challenge-trials-urges-nih-to-follow-suit/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>10 hours ago</ins></p><ins> </ins><p class="epn_channel channel-coronavirus"><ins><a href="https://endpts.com/channel/coronavirus/" title="Channel: Coronavirus"><span>Coronavirus</span> Link: https://endpts.com/channel/coronavirus/ </a></ins></p><ins> </ins><p class="epn_more"><ins><a href="https://endpts.com/news/" title="See Latest Stream">see latest stream Link: https://endpts.com/news/ </a> </ins></p></section><section class="epn_regular_section epn_home_categories_feed"><p class="epn_section_title channel-people"><ins><span><a href="https://endpts.com/channel/people/" title="Channel: People">People Link: https://endpts.com/channel/people/ </a></span> </ins></p><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/gsks-shingrix-leader-guillaume-pfefer-has-jumped-on-board-flagship-to-helm-a-biotech-hybrid-as-afeyans-latest-ceo-partner/" title="GSK’s Shingrix leader Guillaume Pfefer has jumped on board Flagship to helm a biotech hybrid as Afeyan’s latest CEO-partner">GSK’s Shin­grix leader Guil­laume Pfe­fer has jumped on board Flag­ship to helm a biotech hy­brid as Afeyan’s lat­est ... Link: https://endpts.com/gsks-shingrix-leader-guillaume-pfefer-has-jumped-on-board-flagship-to-helm-a-biotech-hybrid-as-afeyans-latest-ceo-partner/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>Yesterday</ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/who-are-the-women-blazing-trails-in-biopharma-rd-and-leading-the-fight-against-covid-19-nominate-them-for-endpoints-special-report/" title="Who are the women blazing trails in biopharma R&amp;D and leading the fight against Covid-19? Nominate them for Endpoints' special report">Who are the women blaz­ing trails in bio­phar­ma R&amp;D and lead­ing the fight against Covid-19? Nom­i­nate them for ... Link: https://endpts.com/who-are-the-women-blazing-trails-in-biopharma-rd-and-leading-the-fight-against-covid-19-nominate-them-for-endpoints-special-report/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>2 days ago</ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/white-house-tries-to-discredit-anthony-fauci-could-he-be-on-his-way-out/" title="White House tries to discredit Anthony Fauci — could he be on his way out?">White House tries to dis­cred­it An­tho­ny Fau­ci — could he be on his way out? Link: https://endpts.com/white-house-tries-to-discredit-anthony-fauci-could-he-be-on-his-way-out/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>4 days ago</ins></p><ins> </ins><p class="epn_section_title channel-startups"><ins><span><a href="https://endpts.com/channel/startups/" title="Channel: Startups">Startups Link: https://endpts.com/channel/startups/ </a></span> </ins></p><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/antibody-legend-tillman-gerngross-is-elbowing-his-way-into-the-covid-19-rd-crusade-i-dont-see-this-ending-anytime-soon/" title="Antibody legend Tillman Gerngross is elbowing his way into the Covid-19 R&amp;D crusade: 'I don’t see this ending anytime soon'">An­ti­body leg­end Till­man Gern­gross is el­bow­ing his way in­to the Covid-19 R&amp;D cru­sade: 'I don’t see this end­ing ... Link: https://endpts.com/antibody-legend-tillman-gerngross-is-elbowing-his-way-into-the-covid-19-rd-crusade-i-dont-see-this-ending-anytime-soon/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>Yesterday</ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/new-biotech-exalys-seeking-to-prevent-postoperative-delirium-launches-with-15-million-in-series-a/" title="New biotech Exalys, seeking to prevent postoperative delirium, launches with $15 million in Series A">New biotech Exalys, seek­ing to pre­vent post­op­er­a­tive delir­i­um, launch­es with $15 mil­lion in Se­ries A Link: https://endpts.com/new-biotech-exalys-seeking-to-prevent-postoperative-delirium-launches-with-15-million-in-series-a/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>Yesterday</ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/after-psilocybin-and-ketamine-a-new-biotech-comes-along-developing-a-drug-scott-gottlieb-tried-to-ban/" title="After psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb fought">Af­ter psilo­cy­bin and ke­t­a­mine, a new biotech comes along de­vel­op­ing a drug Scott Got­tlieb fought Link: https://endpts.com/after-psilocybin-and-ketamine-a-new-biotech-comes-along-developing-a-drug-scott-gottlieb-tried-to-ban/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>Last week</ins></p><ins> </ins><p class="epn_section_title channel-deals"><ins><span><a href="https://endpts.com/channel/deals/" title="Channel: Deals">Deals Link: https://endpts.com/channel/deals/ </a></span> </ins></p><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/gileads-ex-rd-chief-bischofberger-heads-back-to-the-biotech-giant-to-pick-up-a-pair-of-late-stage-drugs-that-had-been-put-aside/" title="Gilead's ex-R&amp;D chief Bischofberger heads back to the biotech giant to pick up a pair of late-stage drugs that had been put aside">Gilead­'s ex-R&amp;D chief Bischof­berg­er heads back to the biotech gi­ant to pick up a pair of late-stage drugs that had ... Link: https://endpts.com/gileads-ex-rd-chief-bischofberger-heads-back-to-the-biotech-giant-to-pick-up-a-pair-of-late-stage-drugs-that-had-been-put-aside/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>Yesterday</ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/sanofi-keeps-foot-on-the-gas-agreeing-to-five-year-collaboration-with-md-anderson/" title="Sanofi keeps foot on the gas, agreeing to five-year collaboration with MD Anderson">Sanofi keeps foot on the gas, agree­ing to five-year col­lab­o­ra­tion with MD An­der­son Link: https://endpts.com/sanofi-keeps-foot-on-the-gas-agreeing-to-five-year-collaboration-with-md-anderson/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>3 days ago</ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/diagnostic-champ-roche-buys-its-way-into-the-ret-title-fight-with-eli-lilly-paying-775m-in-cash-to-blueprint/" title="Diagnostic champ Roche buys its way into the RET title fight with Eli Lilly, paying $775M in cash to Blueprint">Di­ag­nos­tic champ Roche buys its way in­to the RET ti­tle fight with Eli Lil­ly, pay­ing $775M in cash to Blue­print Link: https://endpts.com/diagnostic-champ-roche-buys-its-way-into-the-ret-title-fight-with-eli-lilly-paying-775m-in-cash-to-blueprint/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>3 days ago</ins></p><ins> </ins><p class="epn_section_title channel-ipos"><ins><span><a href="https://endpts.com/channel/ipos/" title="Channel: IPOs">IPOs Link: https://endpts.com/channel/ipos/ </a></span> </ins></p><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/three-more-biotechs-tumble-onto-wall-street-today-raising-475m-as-the-ipo-party-rocks-on/" title="Three more biotechs tumble onto Wall Street today, raising $475M as the IPO party rocks on">Three more biotechs tum­ble on­to Wall Street to­day, rais­ing $475M as the IPO par­ty rocks on Link: https://endpts.com/three-more-biotechs-tumble-onto-wall-street-today-raising-475m-as-the-ipo-party-rocks-on/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>10 hours ago</ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/relay-reaps-400m-ipo-windfall-after-drawing-the-curtain-on-motion-based-drug-design-pipeline/" title="Relay reaps $400M IPO windfall after drawing the curtain on motion-based drug design pipeline">Re­lay reaps $400M IPO wind­fall af­ter draw­ing the cur­tain on mo­tion-based drug de­sign pipeline Link: https://endpts.com/relay-reaps-400m-ipo-windfall-after-drawing-the-curtain-on-motion-based-drug-design-pipeline/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>Yesterday</ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/spacs-are-riding-on-the-biotech-ipo-boom/" title="Billions of dollars worth of SPACs are riding on the biotech IPO boom">Bil­lions of dol­lars worth of SPACs are rid­ing on the biotech IPO boom Link: https://endpts.com/spacs-are-riding-on-the-biotech-ipo-boom/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>3 days ago</ins></p><ins> </ins></section><section class="epn_regular_section epn_homepage_stories epn_homepage_stories_premium"><p class="col-8"><ins></ins></p><h3 class="epn_section_title"><ins><span>Premium stories</span><a href="https://endpts.com/premium/" title="See all Premium Stories">See all Link: https://endpts.com/premium/ </a> </ins></h3><ins> </ins><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/a-neoantigen-pioneer-says-its-tech-is-working-great-so-what-wrecked-the-share-price/" title="A neoantigen pioneer says its tech is working great. So what wrecked the share price?">A neoanti­gen pi­o­neer says its tech is work­ing great. So what wrecked the share price? Link: https://endpts.com/a-neoantigen-pioneer-says-its-tech-is-working-great-so-what-wrecked-the-share-price/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>3 days ago</ins></p><p class="epn_channel channel-bioregnum"><ins><a href="https://endpts.com/channel/bioregnum/" title="Channel: Bioregnum"><span>Bioregnum</span> Link: https://endpts.com/channel/bioregnum/ </a></ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/a-top-analyst-turns-the-spotlight-on-moderna-fueling-a-fast-and-furious-street-race-over-the-future-of-mrna/" title="A top analyst turns the spotlight on Moderna, fueling a fast-and-furious Street race over the future of mRNA">A top an­a­lyst turns the spot­light on Mod­er­na, fu­el­ing a fast-and-fu­ri­ous Street race over the fu­ture of mR­NA Link: https://endpts.com/a-top-analyst-turns-the-spotlight-on-moderna-fueling-a-fast-and-furious-street-race-over-the-future-of-mrna/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>4 days ago</ins></p><p class="epn_channel channel-bioregnum"><ins><a href="https://endpts.com/channel/bioregnum/" title="Channel: Bioregnum"><span>Bioregnum</span> Link: https://endpts.com/channel/bioregnum/ </a></ins></p><p class="epn_channel channel-coronavirus"><ins><a href="https://endpts.com/channel/coronavirus/" title="Channel: Coronavirus"><span>Coronavirus</span> Link: https://endpts.com/channel/coronavirus/ </a></ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/win-or-lose-on-the-marketing-ok-the-fda-just-gunned-down-gsks-bright-hopes-for-their-bcma-therapy/" title="Win or lose on the marketing OK, the FDA just gunned down GSK’s bright hopes for their BCMA therapy">Win or lose on the mar­ket­ing OK, the FDA just gunned down GSK’s bright hopes for their BC­MA ther­a­py Link: https://endpts.com/win-or-lose-on-the-marketing-ok-the-fda-just-gunned-down-gsks-bright-hopes-for-their-bcma-therapy/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>Last week</ins></p><p class="epn_channel channel-bioregnum"><ins><a href="https://endpts.com/channel/bioregnum/" title="Channel: Bioregnum"><span>Bioregnum</span> Link: https://endpts.com/channel/bioregnum/ </a></ins></p><p class="epn_channel channel-regulatory"><ins><a href="https://endpts.com/channel/regulatory/" title="Channel: Regulatory"><span>Regulatory</span> Link: https://endpts.com/channel/regulatory/ </a></ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/the-home-run-count-mega-round-boom-in-biotech-inspired-a-6-7b-feeding-frenzy-7-so-far-this-year/" title="The home run count: The $100M+ mega-round boom in biotech inspired a $7.3B feeding frenzy — so far this year">The home run count: The $100M+ mega-round boom in biotech in­spired a $7.3B feed­ing fren­zy — so far this year Link: https://endpts.com/the-home-run-count-mega-round-boom-in-biotech-inspired-a-6-7b-feeding-frenzy-7-so-far-this-year/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>Last week</ins></p><p class="epn_channel channel-bioregnum"><ins><a href="https://endpts.com/channel/bioregnum/" title="Channel: Bioregnum"><span>Bioregnum</span> Link: https://endpts.com/channel/bioregnum/ </a></ins></p><p class="epn_channel channel-rd"><ins><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span> Link: https://endpts.com/channel/rd/ </a></ins></p></section><section class="epn_regular_section epn_homepage_stories"><p class="col-8"><ins></ins></p><h3 class="epn_section_title"><ins><span>Don't miss</span><a href="https://endpts.com/dont-miss/" title="See all stories">See all Link: https://endpts.com/dont-miss/ </a> </ins></h3><ins> </ins><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/covid-19-roundup-fauci-fires-back-at-white-house-campaign-to-undermine-him/" title="Covid-19 roundup: Russia hackers target US, UK vaccine and drug researchers; Fauci fires back at White House campaign to undermine him">Covid-19 roundup: Rus­sia hack­ers tar­get US, UK vac­cine and drug re­searchers; Fau­ci fires back at White House cam­paign ... Link: https://endpts.com/covid-19-roundup-fauci-fires-back-at-white-house-campaign-to-undermine-him/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>Yesterday</ins></p><p class="epn_channel channel-coronavirus"><ins><a href="https://endpts.com/channel/coronavirus/" title="Channel: Coronavirus"><span>Coronavirus</span> Link: https://endpts.com/channel/coronavirus/ </a></ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/a-neurosurgeon-spent-the-past-30-years-developing-a-neoantigen-tumor-vaccine-now-he-has-112m-to-put-it-to-pivotal-test/" title="A neurosurgeon spent the past 30 years developing a neoantigen tumor vaccine. Now he has $112M for a pivotal test">A neu­ro­sur­geon spent the past 30 years de­vel­op­ing a neoanti­gen tu­mor vac­cine. Now he has $112M for a piv­otal test Link: https://endpts.com/a-neurosurgeon-spent-the-past-30-years-developing-a-neoantigen-tumor-vaccine-now-he-has-112m-to-put-it-to-pivotal-test/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>Yesterday</ins></p><p class="epn_channel channel-venture"><ins><a href="https://endpts.com/channel/venture/" title="Channel: Venture"><span>Venture</span> Link: https://endpts.com/channel/venture/ </a></ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/planning-to-vaccinate-everyone-in-the-us-moderna-outlines-efforts-to-supply-their-covid-19-vaccine-as-manufacturing-ramps-up-ahead-of-phiii/" title="‘Planning to vaccinate everyone in the US,’ Moderna outlines efforts to supply their Covid-19 vaccine as manufacturing ramps up ahead of PhIII">‘Plan­ning to vac­ci­nate every­one in the US,’ Mod­er­na out­lines ef­forts to sup­ply their Covid-19 vac­cine as ... Link: https://endpts.com/planning-to-vaccinate-everyone-in-the-us-moderna-outlines-efforts-to-supply-their-covid-19-vaccine-as-manufacturing-ramps-up-ahead-of-phiii/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>2 days ago</ins></p><p class="epn_channel channel-coronavirus"><ins><a href="https://endpts.com/channel/coronavirus/" title="Channel: Coronavirus"><span>Coronavirus</span> Link: https://endpts.com/channel/coronavirus/ </a></ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/covid-19-roundup-vaccine-by-end-of-2020-ken-frazier-warns-hype-doing-grave-disservice/" title="Covid-19 roundup: Vaccine by end of 2020? Ken Frazier warns hype doing 'grave disservice'">Covid-19 roundup: Vac­cine by end of 2020? Ken Fra­zier warns hype do­ing 'grave dis­ser­vice' Link: https://endpts.com/covid-19-roundup-vaccine-by-end-of-2020-ken-frazier-warns-hype-doing-grave-disservice/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>2 days ago</ins></p><p class="epn_channel channel-coronavirus"><ins><a href="https://endpts.com/channel/coronavirus/" title="Channel: Coronavirus"><span>Coronavirus</span> Link: https://endpts.com/channel/coronavirus/ </a></ins></p></section><section class="epn_regular_section epn_homepage_stories"><p class="col-8"><ins></ins></p><h3 class="epn_section_title"><ins><span>Endpoints Standouts</span> </ins></h3><ins> </ins><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/the-20-under-40-inside-the-next-generation-of-biopharma-leaders/" title="The 20 under 40: Inside the next generation of biopharma leaders">The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers Link: https://endpts.com/the-20-under-40-inside-the-next-generation-of-biopharma-leaders/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>3 months ago</ins></p><p class="epn_channel channel-people"><ins><a href="https://endpts.com/channel/people/" title="Channel: People"><span>People</span> Link: https://endpts.com/channel/people/ </a></ins></p><p class="epn_channel channel-special"><ins><a href="https://endpts.com/channel/special/" title="Channel: Special"><span>Special</span> Link: https://endpts.com/channel/special/ </a></ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/here-are-the-52-new-drugs-approved-by-the-fda-in-2019-who-won-who-lost-and-who-just-survived-to-2020/" title="Here are the 52 new drugs approved by the FDA in 2019. Who won? Who lost? And who just survived to 2020?">Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020? Link: https://endpts.com/here-are-the-52-new-drugs-approved-by-the-fda-in-2019-who-won-who-lost-and-who-just-survived-to-2020/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>6 months ago</ins></p><p class="epn_channel channel-special"><ins><a href="https://endpts.com/channel/special/" title="Channel: Special"><span>Special</span> Link: https://endpts.com/channel/special/ </a></ins></p><p class="epn_channel channel-pharma"><ins><a href="https://endpts.com/channel/pharma/" title="Channel: Pharma"><span>Pharma</span> Link: https://endpts.com/channel/pharma/ </a></ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/special-report-twenty-extraordinary-women-in-biopharma-rd-who-worked-their-way-to-the-top/" title="Special report: Twenty extraordinary women in biopharma R&amp;D who worked their way to the top">Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&amp;D who worked their way to the top Link: https://endpts.com/special-report-twenty-extraordinary-women-in-biopharma-rd-who-worked-their-way-to-the-top/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>8 months ago</ins></p><p class="epn_channel channel-people"><ins><a href="https://endpts.com/channel/people/" title="Channel: People"><span>People</span> Link: https://endpts.com/channel/people/ </a></ins></p><p class="epn_channel channel-rd"><ins><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span> Link: https://endpts.com/channel/rd/ </a></ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/video-celebrating-trial-failures-changing-the-culture-and-allying-with-california-dreamers-rd-chief-hal-barron-talks-about-a-new-era-at-gsk/" title="[Video] Celebrating trial failures, changing the culture and allying with California dreamers: R&amp;D chief Hal Barron talks about a new era at GSK">[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&amp;D chief Hal Bar­ron ... Link: https://endpts.com/video-celebrating-trial-failures-changing-the-culture-and-allying-with-california-dreamers-rd-chief-hal-barron-talks-about-a-new-era-at-gsk/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>9 months ago</ins></p></section><section class="epn_regular_section epn_homepage_category_feed_calendar"><p class="col-8 epn_heading"><ins></ins></p><h3 class="epn_section_title channel-peer-review"><ins><span>Peer review</span> <a href="https://endpts.com/channel/peer-review/" title="See all Peer Review Stories">See all Link: https://endpts.com/channel/peer-review/ </a></ins></h3><ins> </ins><p class="epn_header"><ins><span>Jul</span> </ins></p><p class="epn_text"><ins></ins></p><h3><ins><a href="https://endpts.com/bob-goeltz-bolts-unity-biotechnology-to-become-cfo-at-arcus-biosciences-john-johnston-tapped-for-his-latest-ceo-gig/" title="Bob Goeltz bolts Unity Biotechnology to become CFO at Arcus Biosciences; John Johnson tapped for his latest CEO gig">Bob Goeltz bolts Uni­ty Biotech­nol­o­gy to be­come CFO at Ar­cus Bio­sciences; John John­son tapped for his lat­est CEO gig Link: https://endpts.com/bob-goeltz-bolts-unity-biotechnology-to-become-cfo-at-arcus-biosciences-john-johnston-tapped-for-his-latest-ceo-gig/ </a></ins></h3><ins> </ins><p class="epn_header"><ins><span>Jul</span> </ins></p><p class="epn_text"><ins></ins></p><h3><ins><a href="https://endpts.com/novavax-snags-ben-machielse-for-cmc-and-promotes-a-trio-of-staffers-marty-duvall-lands-another-ceo-post-at-oncopeptides/" title="Novavax snags Ben Machielse for CMC and promotes a trio of staffers; Marty Duvall lands another CEO post at Oncopeptides">No­vavax snags Ben Machielse for CMC and pro­motes a trio of staffers; Mar­ty Du­vall lands an­oth­er CEO post at ... Link: https://endpts.com/novavax-snags-ben-machielse-for-cmc-and-promotes-a-trio-of-staffers-marty-duvall-lands-another-ceo-post-at-oncopeptides/ </a></ins></h3><ins> </ins><p class="epn_header"><ins><span>Jun</span> </ins></p><p class="epn_text"><ins></ins></p><h3><ins><a href="https://endpts.com/inovio-adds-two-to-the-leadership-team-adrian-woolfson-is-out-at-sangamo/" title="Inovio adds two to the leadership team; Adrian Woolfson is out at Sangamo">In­ovio adds two to the lead­er­ship team; Adri­an Woolf­son is out at Sang­amo Link: https://endpts.com/inovio-adds-two-to-the-leadership-team-adrian-woolfson-is-out-at-sangamo/ </a></ins></h3><ins> </ins><p class="epn_header"><ins><span>Jun</span> </ins></p><p class="epn_text"><ins></ins></p><h3><ins><a href="https://endpts.com/boehringer-ingelheim-nabs-new-us-president-and-ceo-astrazeneca-vet-hops-aboard-novavax-as-cmo/" title="Boehringer Ingelheim nabs new US president and CEO; AstraZeneca vet hops aboard Novavax as CMO">Boehringer In­gel­heim nabs new US pres­i­dent and CEO; As­traZeneca vet hops aboard No­vavax as CMO Link: https://endpts.com/boehringer-ingelheim-nabs-new-us-president-and-ceo-astrazeneca-vet-hops-aboard-novavax-as-cmo/ </a></ins></h3><ins> </ins><p class="epn_header"><ins><span>Jun</span> </ins></p><p class="epn_text"><ins></ins></p><h3><ins><a href="https://endpts.com/rising-star-ceo-recounts-path-from-pre-med-to-breakthrough-meds-dendreon-taps-big-pharma-vet-jason-oneill-as-ceo/" title="'Rising star' CEO recounts path from pre-med to breakthrough meds; Dendreon taps Big Pharma vet Jason O'Neill as CEO">'Ris­ing star' CEO re­counts path from pre-med to break­through meds; Den­dreon taps Big Phar­ma vet Ja­son O'Neill as CEO Link: https://endpts.com/rising-star-ceo-recounts-path-from-pre-med-to-breakthrough-meds-dendreon-taps-big-pharma-vet-jason-oneill-as-ceo/ </a></ins></h3><ins> </ins></section><section class="epn_regular_section epn_homepage_category_feed channel-rd"><p class="col-8 epn_heading"><ins></ins></p><h3 class="epn_section_title"><ins><span>R&amp;D channel feed</span></ins></h3><ins> </ins><p class="epn_date"><ins><span>2 days ago</span> </ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline epn_big"><ins><a href="https://endpts.com/a-day-after-moderna-vaccine-results-rumors-swirl-of-pending-astrazeneca-data/" title="A day after Moderna vaccine results, rumors swirl of pending AstraZeneca data">A day af­ter Mod­er­na vac­cine re­sults, ru­mors swirl of pend­ing As­traZeneca da­ta Link: https://endpts.com/a-day-after-moderna-vaccine-results-rumors-swirl-of-pending-astrazeneca-data/ </a></ins></h2><ins> </ins><p><ins>A day af­ter Mod­er­na and the NIH <a href="https://endpts.com/niaid-and-moderna-spell-out-a-robust-immune-response-in-phi-coronavirus-vaccine-test-but-big-questions-remain-to-be-answered/">pub­lished Link: https://endpts.com/niaid-and-moderna-spell-out-a-robust-immune-response-in-phi-coronavirus-vaccine-test-but-big-questions-remain-to-be-answered/ </a> much-an­tic­i­pat­ed da­ta from their Phase I Covid-19 vac­cine tri­al, at­ten­tion is turn­ing to As­traZeneca which, ac­cord­ing to a UK re­port, is ...
</ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/why-pay-4b-for-a-steady-diet-of-disappointment-porges-turns-thumbs-down-on-alexions-ma-strategy-offers-some-pointers/" title="Why pay $4B for a steady diet of disappointment? Porges turns thumbs down on Alexion’s M&amp;A strategy, offers some pointers">Why pay $4B for a steady di­et of dis­ap­point­ment? Porges turns thumbs down on Alex­ion’s M&amp;A strat­e­gy, of­fers some ... Link: https://endpts.com/why-pay-4b-for-a-steady-diet-of-disappointment-porges-turns-thumbs-down-on-alexions-ma-strategy-offers-some-pointers/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>3 days ago</ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/engineering-an-on-off-switch-for-car-t-out-of-yeast-and-jurassic-park/" title="Engineering an on/off switch for CAR-T out of yeast and Jurassic Park">En­gi­neer­ing an on/off switch for CAR-T out of yeast and Juras­sic Park Link: https://endpts.com/engineering-an-on-off-switch-for-car-t-out-of-yeast-and-jurassic-park/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>4 days ago</ins></p><p class="epn_channel channel-cell-gene-tx"><ins><a href="https://endpts.com/channel/cell-gene-tx/" title="Channel: Cell/Gene Tx"><span>Cell/Gene Tx</span> Link: https://endpts.com/channel/cell-gene-tx/ </a></ins></p><p class="epn_badge"><ins>latest in R&amp;D</ins></p><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/full-brilinta-study-results-show-the-blood-thinner-reduces-rate-of-secondary-stroke/" title="Full Brilinta study results show the blood thinner reduces rate of secondary stroke">Full Bril­in­ta study re­sults show the blood thin­ner re­duces rate of sec­ondary stroke Link: https://endpts.com/full-brilinta-study-results-show-the-blood-thinner-reduces-rate-of-secondary-stroke/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>Yesterday</ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/the-1b-merck-bayer-drug-that-divided-cardiologists-in-march-gets-priority-review/" title="The $1B Merck-Bayer drug that divided cardiologists in March gets priority review">The $1B Mer­ck-Bay­er drug that di­vid­ed car­di­ol­o­gists in March gets pri­or­i­ty re­view Link: https://endpts.com/the-1b-merck-bayer-drug-that-divided-cardiologists-in-march-gets-priority-review/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>Yesterday</ins></p><ins> </ins><p class="epn_channel channel-regulatory"><ins><a href="https://endpts.com/channel/regulatory/" title="Channel: Regulatory"><span>Regulatory</span> Link: https://endpts.com/channel/regulatory/ </a></ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/milliporesigma-to-build-new-20-million-12000-square-foot-lab-in-switzerland/" title="MilliporeSigma to build new $20 million, 12,000-square-foot lab in Switzerland">Mil­li­pore­Sig­ma to build new $20 mil­lion, 12,000-square-foot lab in Switzer­land Link: https://endpts.com/milliporesigma-to-build-new-20-million-12000-square-foot-lab-in-switzerland/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>2 days ago</ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/longevity-as-a-service-insilico-spins-off-ai-biotech-that-trains-deep-learning-on-anti-aging-treatments/" title="'Longevity as a service': Insilico spins off AI biotech that trains deep learning on anti-aging treatments">'Longevi­ty as a ser­vice': In­sil­i­co spins off AI biotech that trains deep learn­ing on an­ti-ag­ing treat­ments Link: https://endpts.com/longevity-as-a-service-insilico-spins-off-ai-biotech-that-trains-deep-learning-on-anti-aging-treatments/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>2 days ago</ins></p><ins> </ins><p class="epn_channel channel-venture"><ins><a href="https://endpts.com/channel/venture/" title="Channel: Venture"><span>Venture</span> Link: https://endpts.com/channel/venture/ </a></ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/cytokinetics-nabs-chinese-partner-up-to-450m-as-cv-becomes-company-focus/" title="Cytokinetics nabs Chinese partner, up to $450M as CV becomes company focus">Cy­to­ki­net­ics nabs Chi­nese part­ner, up to $450M as CV be­comes com­pa­ny fo­cus Link: https://endpts.com/cytokinetics-nabs-chinese-partner-up-to-450m-as-cv-becomes-company-focus/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>3 days ago</ins></p><ins> </ins><p class="epn_more"><ins><a href="https://endpts.com/channel/rd/" title="See Latest Stories in R&amp;D Channel">see latest stories Link: https://endpts.com/channel/rd/ </a> </ins></p></section><p class="col-8 epn_heading"><ins></ins></p><h3 class="epn_section_title"><ins><span>Pharma channel feed</span></ins></h3><ins> </ins><p class="epn_date"><ins><span>Last week</span> </ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline epn_big"><ins><a href="https://endpts.com/top-biotech-analyst-projects-a-gloomy-outlook-for-pfizers-jak-portfolio/" title="Top biotech analyst projects a gloomy outlook for Pfizer's JAK portfolio">Top biotech an­a­lyst projects a gloomy out­look for Pfiz­er's JAK port­fo­lio Link: https://endpts.com/top-biotech-analyst-projects-a-gloomy-outlook-for-pfizers-jak-portfolio/ </a></ins></h2> <p>Many in the phar­ma world are hop­ing — bet­ter yet, ex­pect­ing — JAK in­hibitors to pro­vide one of the next big boons for the in­dus­try. <a href="https://endpts.com/pfizer-jumps-into-the-heated-phiii-race-for-new-wave-jak-inhibitors-but-safety-frets-loom-large/">Few have in­vest­ed</a> as <a href="https://endpts.com/pfizers-jak1-challenger-to-dupixent-shines-in-another-phiii-but-safety-issues-still-cast-a-shadow/">heav­i­ly</a> in this area as ...
</p> <p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/immunomedics-spells-out-pfs-benefit-of-trodelvy-in-mtnbc-hunting-a-full-ok-just-weeks-after-accelerated-approval/" title="Immunomedics spells out PFS benefit of Trodelvy in mTNBC, hunting a full OK just weeks after accelerated approval">Im­munomedics spells out PFS ben­e­fit of Trodelvy in mTNBC, hunt­ing a full OK just weeks af­ter ac­cel­er­at­ed ap­proval Link: https://endpts.com/immunomedics-spells-out-pfs-benefit-of-trodelvy-in-mtnbc-hunting-a-full-ok-just-weeks-after-accelerated-approval/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>Last week</ins></p><p class="epn_channel channel-rd"><ins><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span> Link: https://endpts.com/channel/rd/ </a></ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/a-little-biotech-slaps-back-at-a-criminal-short-attack-vowing-to-pursue-a-prosecution-of-their-case/" title="A little biotech slaps back at a 'criminal' short attack, vowing to pursue a prosecution of their case">A lit­tle biotech slaps back at a 'crim­i­nal' short at­tack, vow­ing to pur­sue a pros­e­cu­tion of their case Link: https://endpts.com/a-little-biotech-slaps-back-at-a-criminal-short-attack-vowing-to-pursue-a-prosecution-of-their-case/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>Last week</ins></p><p class="epn_badge"><ins>latest in Pharma</ins></p><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/which-drug-developers-offer-trump-a-quick-game-changing-solution-as-the-pandemic-roars-back-eli-lilly-and-abcellera-look-to-break-out-of-the-pack/" title="Which drug developers offer Trump a quick, game-changing ‘solution’ as the pandemic roars back? Eli Lilly and AbCellera look to break out of the pack">Which drug de­vel­op­ers of­fer Trump a quick, game-chang­ing ‘so­lu­tion’ as the pan­dem­ic roars back? Eli Lil­ly and Ab­Cellera look to break out of the pack Link: https://endpts.com/which-drug-developers-offer-trump-a-quick-game-changing-solution-as-the-pandemic-roars-back-eli-lilly-and-abcellera-look-to-break-out-of-the-pack/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>Last week</ins></p><ins> </ins><p class="epn_channel channel-bioregnum"><ins><a href="https://endpts.com/channel/bioregnum/" title="Channel: Bioregnum"><span>Bioregnum</span> Link: https://endpts.com/channel/bioregnum/ </a></ins></p><p class="epn_channel channel-coronavirus"><ins><a href="https://endpts.com/channel/coronavirus/" title="Channel: Coronavirus"><span>Coronavirus</span> Link: https://endpts.com/channel/coronavirus/ </a></ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/novartis-pays-672m-for-kickback-scheme-as-vas-narasimhan-tries-to-distance-pharma-giant-from-shady-behavior/" title="Novartis pays $678M for kickback scheme as Vas Narasimhan tries to distance pharma giant from shady behavior">No­var­tis pays $678M for kick­back scheme as Vas Narasimhan tries to dis­tance phar­ma gi­ant from shady be­hav­ior Link: https://endpts.com/novartis-pays-672m-for-kickback-scheme-as-vas-narasimhan-tries-to-distance-pharma-giant-from-shady-behavior/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>3 weeks ago</ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/novartis-loses-biosimilar-appeal-as-court-upholds-a-31-year-monopoly-by-amgens-enbrel/" title="Novartis loses biosimilar appeal as court upholds a 31-year monopoly by Amgen's Enbrel">No­var­tis los­es biosim­i­lar ap­peal as court up­holds a 31-year mo­nop­oly by Am­gen's En­brel Link: https://endpts.com/novartis-loses-biosimilar-appeal-as-court-upholds-a-31-year-monopoly-by-amgens-enbrel/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>3 weeks ago</ins></p><ins> </ins><p class="epn_channel channel-regulatory"><ins><a href="https://endpts.com/channel/regulatory/" title="Channel: Regulatory"><span>Regulatory</span> Link: https://endpts.com/channel/regulatory/ </a></ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/an-experienced-biotech-is-stitched-together-from-transpacific-parts-with-265-staffers-and-a-focus-on-new-biology/" title="An experienced biotech is stitched together from transpacific parts, with 265 staffers and a focus on ‘new biology’">An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new bi­ol­o­gy’ Link: https://endpts.com/an-experienced-biotech-is-stitched-together-from-transpacific-parts-with-265-staffers-and-a-focus-on-new-biology/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>3 weeks ago</ins></p><ins> </ins><p class="epn_channel channel-deals"><ins><a href="https://endpts.com/channel/deals/" title="Channel: Deals"><span>Deals</span> Link: https://endpts.com/channel/deals/ </a></ins></p><p class="epn_channel channel-rd"><ins><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span> Link: https://endpts.com/channel/rd/ </a></ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/new-standard-of-care-fda-hands-pfizer-merck-kgaa-an-ok-for-bavencio-in-bladder-cancer/" title="New standard of care? FDA hands Pfizer, Merck KGaA an OK for Bavencio in bladder cancer">New stan­dard of care? FDA hands Pfiz­er, Mer­ck KGaA an OK for Baven­cio in blad­der can­cer Link: https://endpts.com/new-standard-of-care-fda-hands-pfizer-merck-kgaa-an-ok-for-bavencio-in-bladder-cancer/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>3 weeks ago</ins></p><ins> </ins><p class="epn_channel channel-regulatory"><ins><a href="https://endpts.com/channel/regulatory/" title="Channel: Regulatory"><span>Regulatory</span> Link: https://endpts.com/channel/regulatory/ </a></ins></p><ins> </ins><p class="epn_more"><ins><a href="https://endpts.com/channel/pharma/" title="See Latest Stories in Pharma Channel">see latest stories Link: https://endpts.com/channel/pharma/ </a> </ins></p><section class="epn_regular_section epn_homepage_category_feed channel-coronavirus"><p class="col-8 epn_heading"><ins></ins></p><h3 class="epn_section_title"><ins><span>Coronavirus channel feed</span></ins></h3><ins> </ins><p class="epn_date"><ins><span>3 days ago</span> </ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline epn_big"><ins><a href="https://endpts.com/more-warp-speed-contracts-coming-vaccine-production-to-begin-in-4-6-weeks-officials/" title="More Warp Speed contracts coming, vaccine production to begin in 4-6 weeks — officials">More Warp Speed con­tracts com­ing, vac­cine pro­duc­tion to be­gin in 4-6 weeks — of­fi­cials Link: https://endpts.com/more-warp-speed-contracts-coming-vaccine-production-to-begin-in-4-6-weeks-officials/ </a></ins></h2><ins> </ins><p><ins>Op­er­a­tion Warp Speed has al­ready hand­ed out 4 of what they once said would be 3-5 ma­jor con­tracts to de­vel­op Covid-19 vac­cines, but ad­min­is­tra­tion of­fi­cials in­di­cat­ed Mon­day that more would ...
</ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/covid-19-roundup-albert-bourla-sees-a-pfizer-vaccine-by-october-leading-chinese-vaccine-data-from-sinovac-could-come-same-time/" title="Covid-19 roundup: CanSino eyes more overseas PhIII sites as Canada trial reportedly stalls; Indian drugmaker surges on 30-person data">Covid-19 roundup: CanSi­no eyes more over­seas PhI­II sites as Cana­da tri­al re­port­ed­ly stalls; In­di­an drug­mak­er surges ... Link: https://endpts.com/covid-19-roundup-albert-bourla-sees-a-pfizer-vaccine-by-october-leading-chinese-vaccine-data-from-sinovac-could-come-same-time/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>4 days ago</ins></p><p class="epn_channel channel-rd"><ins><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span> Link: https://endpts.com/channel/rd/ </a></ins></p><p class="epn_title"><ins></ins></p><h2 class="epn_headline"><ins><a href="https://endpts.com/covid-19-roundup-clinical-trials-have-returned-for-now-biontechs-other-vaccine-partnership-hits-the-clinic/" title="Covid-19 roundup: After Trump attack, doctors, researchers flock to defend Fauci; Philip Morris-backed Medicago begins dosing tobacco-based vaccine">Covid-19 roundup: Af­ter Trump at­tack, doc­tors, re­searchers flock to de­fend Fau­ci; Philip Mor­ris-backed Med­ica­go ... Link: https://endpts.com/covid-19-roundup-clinical-trials-have-returned-for-now-biontechs-other-vaccine-partnership-hits-the-clinic/ </a></ins></h2><ins> </ins><p class="epn_time"><ins>3 days ago</ins></p><p class="epn_badge"><ins>latest in Coronavirus</ins></p><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/experts-urge-transparency-advisory-committee-review-for-covid-19-vaccines/" title="Experts urge transparency, advisory committee review for Covid-19 vaccines">Ex­perts urge trans­paren­cy, ad­vi­so­ry com­mit­tee re­view for Covid-19 vac­cines Link: https://endpts.com/experts-urge-transparency-advisory-committee-review-for-covid-19-vaccines/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>2 days ago</ins></p><ins> </ins><p class="epn_channel channel-regulatory"><ins><a href="https://endpts.com/channel/regulatory/" title="Channel: Regulatory"><span>Regulatory</span> Link: https://endpts.com/channel/regulatory/ </a></ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/gilead-surges-on-another-batch-of-non-randomized-data-this-time-they-say-it-shows-remdesivir-may-improve-mortality/" title="Gilead boasts of positive remdesivir data on mortality — but their analysis provokes the skeptics">Gilead boasts of pos­i­tive remde­sivir da­ta on mor­tal­i­ty — but their analy­sis pro­vokes the skep­tics Link: https://endpts.com/gilead-surges-on-another-batch-of-non-randomized-data-this-time-they-say-it-shows-remdesivir-may-improve-mortality/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>Last week</ins></p><ins> </ins><p class="epn_channel channel-rd"><ins><a href="https://endpts.com/channel/rd/" title="Channel: R&amp;D"><span>R&amp;D</span> Link: https://endpts.com/channel/rd/ </a></ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/peter-marks-on-covid-19-vaccine-efficacy-euas-and-challenge-trials/" title="Peter Marks on Covid-19 vaccine efficacy, EUAs and challenge trials">Pe­ter Marks on Covid-19 vac­cine ef­fi­ca­cy, EUAs and chal­lenge tri­als Link: https://endpts.com/peter-marks-on-covid-19-vaccine-efficacy-euas-and-challenge-trials/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>Last week</ins></p><ins> </ins><p class="epn_channel channel-regulatory"><ins><a href="https://endpts.com/channel/regulatory/" title="Channel: Regulatory"><span>Regulatory</span> Link: https://endpts.com/channel/regulatory/ </a></ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/trial-on-shinzo-abes-once-favorite-antiviral-is-inconclusive-uk-leaves-eu-vaccine-talks/" title="Covid-19 roundup: BioNTech going head-to-head with Moderna as PhIII mRNA launch looms; Trial on Shinzo Abe’s once-favorite antiviral is inconclusive">Covid-19 roundup: BioN­Tech go­ing head-to-head with Mod­er­na as PhI­II mR­NA launch looms; Tri­al on Shin­zo Abe’s once-fa­vorite an­tivi­ral is in­con­clu­sive Link: https://endpts.com/trial-on-shinzo-abes-once-favorite-antiviral-is-inconclusive-uk-leaves-eu-vaccine-talks/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>Last week</ins></p><ins> </ins><p class="epn_item"><ins></ins></p><h3 class="epn_headline"><ins><a href="https://endpts.com/nih-kicks-off-covid-19-vaccine-monoclonal-antibody-research-network/" title="NIH kicks off Covid-19 vaccine, monoclonal antibody research network">NIH kicks off Covid-19 vac­cine, mon­o­clon­al an­ti­body re­search net­work Link: https://endpts.com/nih-kicks-off-covid-19-vaccine-monoclonal-antibody-research-network/ </a> </ins></h3><ins> </ins><p class="epn_time"><ins>Last week</ins></p><ins> </ins><p class="epn_more"><ins><a href="https://endpts.com/channel/coronavirus/" title="See Latest Stories in Coronavirus Channel">see latest stories Link: https://endpts.com/channel/coronavirus/ </a> </ins></p></section><p class="col-8"><ins></ins></p><h3 class="epn_ux_modal_caption"><ins><span class="epn_golden">Sign in to your account</span> </ins></h3><ins> </ins><h3 class="epn_ux_modal_caption"><ins><span>e-mail</span> </ins></h3><ins> </ins><h3 class="epn_ux_modal_caption"><ins><span>password</span> </ins></h3><ins> </ins><p class="col-8"><ins></ins></p><h3 class="epn_ux_modal_caption"><ins><span class="epn_golden">request magic link</span> </ins></h3><ins> </ins><p><ins>If you're already an Endpoints subscriber, enter your email below for a magic link that lets you sign in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.</ins></p><ins> </ins><h3 class="epn_ux_modal_caption"><ins><span>email</span> </ins></h3><ins> </ins><p class="col-8"><ins></ins></p><h3 class="epn_ux_modal_caption"><ins><span class="epn_golden">reset password</span> </ins></h3><ins> </ins><p><ins>We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.</ins></p> </section> <del><a href="https://endpts.com/top-biotech-analyst-projects-a-gloomy-outlook-for-pfizers-jak-portfolio/" title="Top biotech analyst projects a gloomy outlook for Pfizer's JAK portfolio" class="epn_ux_button epn_more">READ MORE Link: https://endpts.com/top-biotech-analyst-projects-a-gloomy-outlook-for-pfizers-jak-portfolio/ </a></del> </div>